Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan · Delayed Price · Currency is JPY 1,915.50
+27.00 (1.43%)
May 29, 2026, 3:30 PM JST
Santen Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 291,624 | 300,004 | 301,965 | 279,037 | 266,257 | |
Revenue Growth (YoY) | -2.79% | -0.65% | 8.22% | 4.80% | 6.67% |
Cost of Revenue | 121,881 | 128,977 | 123,256 | 112,950 | 109,671 |
Gross Profit | 169,743 | 171,027 | 178,709 | 166,087 | 156,586 |
Selling, General & Admin | 89,570 | 83,299 | 86,880 | 134,072 | 120,610 |
Research & Development | 26,185 | 24,103 | 25,416 | - | - |
Other Operating Expenses | -2,583 | 1,638 | -282 | -3,285 | 101 |
Operating Expenses | 121,945 | 122,732 | 126,524 | 130,787 | 120,711 |
Operating Income | 47,798 | 48,295 | 52,185 | 35,300 | 35,875 |
Interest Expense | -1,994 | -1,083 | -831 | -476 | -249 |
Interest & Investment Income | 1,639 | 1,623 | 1,262 | 1,086 | 1,063 |
Earnings From Equity Investments | - | -685 | -7,575 | -2,362 | -1,604 |
Currency Exchange Gain (Loss) | - | 1,651 | -121 | -663 | -959 |
Other Non Operating Income (Expenses) | -1 | 15 | -198 | -118 | 371 |
EBT Excluding Unusual Items | 47,442 | 49,816 | 44,722 | 32,767 | 34,497 |
Merger & Restructuring Charges | - | - | -5,829 | -3,225 | - |
Gain (Loss) on Sale of Investments | - | -708 | -1,046 | -228 | 800 |
Gain (Loss) on Sale of Assets | - | -286 | 738 | -554 | 412 |
Asset Writedown | - | -1,302 | -7,547 | -34,508 | 245 |
Legal Settlements | - | - | -410 | -51 | -338 |
Other Unusual Items | - | -39 | -755 | - | - |
Pretax Income | 47,442 | 47,481 | 29,873 | -5,799 | 35,616 |
Income Tax Expense | 9,881 | 11,628 | 3,171 | 9,184 | 8,427 |
Earnings From Continuing Operations | 37,561 | 35,853 | 26,702 | -14,983 | 27,189 |
Minority Interest in Earnings | -192 | 403 | -60 | 35 | 29 |
Net Income | 37,369 | 36,256 | 26,642 | -14,948 | 27,218 |
Preferred Dividends & Other Adjustments | - | 9 | 8 | 7 | 6 |
Net Income to Common | 37,369 | 36,247 | 26,634 | -14,955 | 27,212 |
Net Income Growth | 3.07% | 36.09% | - | - | 298.51% |
Shares Outstanding (Basic) | 328 | 349 | 367 | 387 | 400 |
Shares Outstanding (Diluted) | 328 | 350 | 368 | 387 | 400 |
Shares Change (YoY) | -6.10% | -5.01% | -4.98% | -3.26% | 0.02% |
EPS (Basic) | 114.06 | 103.98 | 72.59 | -38.60 | 68.07 |
EPS (Diluted) | 113.80 | 103.68 | 72.37 | -38.60 | 67.97 |
EPS Growth | 9.76% | 43.26% | - | - | 298.44% |
Free Cash Flow | 36,656 | 54,266 | 63,330 | 19,870 | 28,699 |
Free Cash Flow Per Share | 111.63 | 155.18 | 172.03 | 51.29 | 71.67 |
Dividend Per Share | - | 36.000 | 33.000 | 32.000 | 32.000 |
Dividend Growth | - | 9.09% | 3.13% | - | 14.29% |
Gross Margin | 58.21% | 57.01% | 59.18% | 59.52% | 58.81% |
Operating Margin | 16.39% | 16.10% | 17.28% | 12.65% | 13.47% |
Profit Margin | 12.81% | 12.08% | 8.82% | -5.36% | 10.22% |
Free Cash Flow Margin | 12.57% | 18.09% | 20.97% | 7.12% | 10.78% |
EBITDA | 66,156 | 66,243 | 70,363 | 52,549 | 52,930 |
EBITDA Margin | 22.68% | 22.08% | 23.30% | 18.83% | 19.88% |
D&A For EBITDA | 18,358 | 17,948 | 18,178 | 17,249 | 17,055 |
EBIT | 47,798 | 48,295 | 52,185 | 35,300 | 35,875 |
EBIT Margin | 16.39% | 16.10% | 17.28% | 12.65% | 13.47% |
Effective Tax Rate | 20.83% | 24.49% | 10.62% | - | 23.66% |
Advertising Expenses | - | 13,310 | 18,278 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.